SCHEMBL3566023

SCHEMBL3566023

Cc1nn(-c2ccc(Sc3cccc(C4(C(N)=O)CCOCC4)c3)cc2)c(=O)n1CCN1CCOCC1

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 7/20 0.60
AVPR1B P47901 4/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CTSK P43235 1/20 0.34
F10 P00742 1/20 0.34
CNR2 P34972 2/20 0.33
GAA P10253 1/20 0.33
CNR1 P21554 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HTT P42858 1/20 0.33
ABL1 P00519 1/20 0.33
OPRM1 P35372 1/20 0.33
OPRD1 P41143 1/20 0.33
RIN1 Q13671 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3567948 0.92 ALOX5 (0.61) ALOX5AVPR1B
SCHEMBL3567079 0.92 ALOX5 (0.61) ALOX5AVPR1BCTSKALDH1A1
SCHEMBL3574400 0.91 ALOX5 (0.61) ALOX5AVPR1B
SCHEMBL3572905 0.90 ALOX5 (0.60) ALOX5CNR2CNR1KDM4EALDH1A1
SCHEMBL3566842 0.90 ALOX5 (0.63) ALOX5AVPR1B
SCHEMBL3576330 0.88 ALOX5 (0.61) ALOX5AVPR1BGAAALDH1A1
SCHEMBL3571273 0.87 ALOX5 (0.60) ALOX5AVPR1BALDH1A1HTT
SCHEMBL3572355 0.86 ALOX5 (0.58) ALOX5ALDH1A1OPRM1
SCHEMBL3576764 0.85 ALOX5 (0.41) ALOX5AVPR1BSMN1; SMN2L3MBTL1CTSK
SCHEMBL3573625 0.83 ALOX5 (0.63) ALOX5AVPR1BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674811-B2 5-lipoxygenase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2010-03-09 US claimed
US-20080021080-A1 5-LIPOXYGENASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2008-01-24 US claimed
EP-1834953-A1 Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors Ranbaxy Laboratories Limited (IN) 2007-09-19 EP claimed
US-7674811-B2 5-lipoxygenase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2010-03-09 US disclosed
US-20080021080-A1 5-LIPOXYGENASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2008-01-24 US disclosed
EP-1834953-A1 Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors Ranbaxy Laboratories Limited (IN) 2007-09-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021080-A1 5-LIPOXYGENASE INHIBITORS ALOX5, ALOX15B, ALOX15 ALOX5 1/4885AVPR1B 3202/4885SMN1; SMN2 4751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.